SAREPTA THERAPEUTICS INC's ticker is SRPT and the CUSIP is 803607100. A total of 305 filers reported holding SAREPTA THERAPEUTICS INC in Q3 2021. The put-call ratio across all filers is 0.70 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $2,802,527 | +8.8% | 23,163 | +3.0% | 0.00% | +33.3% |
| Q2 2023 | $2,576,471 | -16.3% | 22,498 | +0.7% | 0.00% | -25.0% |
| Q1 2023 | $3,078,571 | +8.3% | 22,336 | +1.8% | 0.00% | 0.0% |
| Q4 2022 | $2,843,115 | +18.9% | 21,941 | +1.4% | 0.00% | 0.0% |
| Q3 2022 | $2,392,000 | +44.3% | 21,643 | -2.1% | 0.00% | +33.3% |
| Q2 2022 | $1,658,000 | -4.1% | 22,115 | -0.0% | 0.00% | 0.0% |
| Q1 2022 | $1,728,000 | -13.3% | 22,116 | -0.0% | 0.00% | 0.0% |
| Q4 2021 | $1,992,000 | -7.9% | 22,121 | -5.4% | 0.00% | -25.0% |
| Q3 2021 | $2,162,000 | +3.1% | 23,374 | -13.3% | 0.00% | 0.0% |
| Q2 2021 | $2,096,000 | -13.7% | 26,962 | -17.2% | 0.00% | -20.0% |
| Q1 2021 | $2,428,000 | -59.7% | 32,577 | -7.9% | 0.01% | -61.5% |
| Q4 2020 | $6,032,000 | +24.0% | 35,383 | +2.2% | 0.01% | 0.0% |
| Q3 2020 | $4,863,000 | +9.1% | 34,630 | +24.5% | 0.01% | 0.0% |
| Q2 2020 | $4,459,000 | +66.4% | 27,807 | +1.5% | 0.01% | +30.0% |
| Q1 2020 | $2,679,000 | -65.3% | 27,387 | -54.3% | 0.01% | -56.5% |
| Q4 2019 | $7,728,000 | +96.1% | 59,888 | +14.5% | 0.02% | +76.9% |
| Q3 2019 | $3,941,000 | -76.4% | 52,325 | -52.3% | 0.01% | -76.8% |
| Q2 2019 | $16,683,000 | +7.9% | 109,790 | -15.3% | 0.06% | 0.0% |
| Q1 2019 | $15,458,000 | +101.8% | 129,690 | +84.7% | 0.06% | +80.6% |
| Q4 2018 | $7,661,000 | -40.3% | 70,203 | -11.6% | 0.03% | -35.4% |
| Q3 2018 | $12,828,000 | +36.4% | 79,427 | +11.6% | 0.05% | +29.7% |
| Q2 2018 | $9,404,000 | +46.1% | 71,147 | -18.1% | 0.04% | +42.3% |
| Q1 2018 | $6,435,000 | +17.2% | 86,850 | -12.0% | 0.03% | +8.3% |
| Q4 2017 | $5,491,000 | +16.7% | 98,683 | -4.9% | 0.02% | +9.1% |
| Q3 2017 | $4,706,000 | +30.4% | 103,756 | -3.1% | 0.02% | +22.2% |
| Q2 2017 | $3,610,000 | +9.8% | 107,100 | -3.6% | 0.02% | 0.0% |
| Q1 2017 | $3,289,000 | +20.7% | 111,125 | +11.9% | 0.02% | +5.9% |
| Q4 2016 | $2,724,000 | -2.9% | 99,325 | +117.3% | 0.02% | -5.6% |
| Q3 2016 | $2,806,000 | +123.8% | 45,700 | -30.5% | 0.02% | +100.0% |
| Q2 2016 | $1,254,000 | +18.6% | 65,800 | +21.5% | 0.01% | +12.5% |
| Q1 2016 | $1,057,000 | -48.3% | 54,150 | +2.3% | 0.01% | -52.9% |
| Q4 2015 | $2,043,000 | +135.1% | 52,950 | +95.7% | 0.02% | +112.5% |
| Q3 2015 | $869,000 | 0.0% | 27,050 | -5.3% | 0.01% | 0.0% |
| Q2 2015 | $869,000 | +196.6% | 28,550 | +29.5% | 0.01% | +166.7% |
| Q1 2015 | $293,000 | +12.3% | 22,050 | +22.2% | 0.00% | 0.0% |
| Q4 2014 | $261,000 | +20.8% | 18,050 | +76.1% | 0.00% | 0.0% |
| Q3 2014 | $216,000 | +24.1% | 10,250 | +75.2% | 0.00% | +50.0% |
| Q2 2014 | $174,000 | +25.2% | 5,850 | +0.9% | 0.00% | 0.0% |
| Q1 2014 | $139,000 | +768.8% | 5,800 | +657.2% | 0.00% | – |
| Q4 2013 | $16,000 | +433.3% | 766 | +1060.6% | 0.00% | – |
| Q3 2013 | $3,000 | 0.0% | 66 | 0.0% | 0.00% | – |
| Q2 2013 | $3,000 | – | 66 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Perceptive Advisors | 2,878,979 | $69,182,000 | 7.27% |
| Eventide Asset Management | 259,100 | $6,226,000 | 0.97% |
| GLADE BROOK CAPITAL PARTNERS LLC | 251,000 | $6,032,000 | 0.93% |
| IMS Capital Management | 32,215 | $774,000 | 0.91% |
| Perceptive Advisors | 350,000 | $8,413,000 | 0.88% |
| Benchmark Capital Advisors | 34,900 | $839,000 | 0.58% |
| BECK CAPITAL MANAGEMENT, LLC | 24,744 | $636,000 | 0.49% |
| SABBY MANAGEMENT, LLC | 352,100 | $8,461,000 | 0.47% |
| Hatteras Alternative Mutual Funds, LLC | 39,404 | $947,000 | 0.46% |
| Potomac Capital Management, Inc. | 22,100 | $531,000 | 0.45% |